Estrogen and progesterone receptors in breast cancer.

  title={Estrogen and progesterone receptors in breast cancer.},
  author={Cheng Har Yip and Anthony Rhodes},
  journal={Future oncology},
  volume={10 14},
Breast cancer is the most common cancer in women worldwide. The majority of breast cancers show overexpression of estrogen receptors (ERs) and progesterone receptors (PRs). The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers. Since information about ER and PR is vital for patient management, quality assurance is important to ensure accurate testing. In recent… 

Tables from this paper

Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer

A brief overview of various factors that are responsible for provoking breast cancer in women and design strategies recently used by the various research groups across the world for antagonizing or demodulating ER-α are provided.

Notch Signaling Pathway and Endocrine Resistance in Breast Cancer

The latest progress on the investigation of Notch signaling pathway in breast cancer endocrine resistance is summarized and the potential mechanisms include regulation of ER, promotion of cancer stem cell phenotype and mesenchymal cell ratio, alteration of the local tumor microenvironment and cell cycle.

Increased expression of thyroid hormone receptor alpha and estrogen receptor alpha in breast cancer associated with thyroid cancer.

  • Ye An KimYoung A. Kim Y. J. Park
  • Medicine, Biology
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2021

Role of Estrogen Receptor-Positive/Negative Ratios in Regulating Breast Cancer

The results indicate that during HR+ breast cancer treatment, the ERα+/ERα− ratio may be a useful predictor and should be evaluated further.

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women

Quantitative immunohistochemical measures of ER, especially the ER/PR/HER2 score, are supported as a more precise predictor for breast cancer-specific mortality risk than a simple determination of ER positivity.

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma

The aim of the current review is to describe the drugs that could possibly be utilized in endocrine therapy for the treatment of high-grade gliomas, analyze their interaction with ERs, and explore the involvement of these drugs and receptors in resistance to standard chemotherapy.


Of the six parameters studied, histological grade, hormone receptor expression and HER-2/neu overexpression correlated significantly with other parameters, but menopausal status did not correlate with any parameter.

MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers

The disruptive functions of several miRNAs and lncRNAs seen in dysregulated cancer metabolism are described, with a focus on the gene encoding for aromatase (CYP19A1 gene) and estrogen synthesis as a novel therapeutic approach for treating ER-positive breast and ovarian cancers.

Current biomarkers of canine mammary tumors

Estimation of biomarkers in cases of CMT is still not a common practice, and more detailed research should be done, but carcinoembryonic antigen and cancer antigen 15-3 (CA15-3), while poorly studied, seem to be good biomarkers, especially for the early detection and prognosis of C MT.



Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

The biology and etiology of ER-positive/PR-negative breast cancer is discussed, highlighting recent data on molecular cross talk between ER and growth factor signaling pathways and demonstrating how PR might be a useful marker of these activities.

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

  • L. LindströmE. Karlsson J. Bergh
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Investigating whether hormonal receptors and human epidermal growth factor receptor 2 (HER2) change throughout tumor progression, because this may alter patient management, found marker investigations at relapse may potentially improve patient management and survival.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

It is hypothesized that ER+/PR- breast tumors are more likely than ER-/PR+ breast tumors to have an aggressive phenotype, to express HER-1 and overexpress HER-2, and are less likely to benefit from tamoxifen adjuvant therapy.

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

  • M. DowsettJ. Houghton M. Baum
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
Measurement of PgR status in ER-negative patients defines a group of patients that benefit from tamoxifen but would be excluded from tamxifen therapy on the basis of ER status alone, consistent with HER2 positive tumours being resistant to tamoxIFen.

Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.

Multivariate analyses support the conclusion that, while nodes and ER exert strong prognostic influences in both PF- and PFT-treated patients, the PR content of tumors is a stronger predictor of the effectiveness of PFT therapy than is ER content.

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study

Absence of PR expression should be re-evaluated as a biomarker for poor prognosis in ER-positive breast cancer and such patients considered for additional systemic therapy.

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women

Quantitative immunohistochemical measures of ER, especially the ER/PR/HER2 score, are supported as a more precise predictor for breast cancer-specific mortality risk than a simple determination of ER positivity.

Risk factors for breast cancer according to estrogen and progesterone receptor status.

Incidence rates and risk factors for breast cancer differ according to ER and PR status, and breast cancer cases should be divided according to the ER andPR status of the tumor.

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

IHC is superior to the LBA for assessing ER status in primary breast cancer because it is easier, safer, and less expensive, and has an equivalent or better ability to predict response to adjuvant endocrine therapy.

Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods.

It is demonstrated that immunocytochemical estrogen receptor analysis was of prognostic significance and the relationship between estrogen receptor status and disease-free interval was less strong than with survival.